|
End-of-day quote
Korea S.E.
19/10/2026
|
5-day change | 1st Jan Change | ||
| 1,071,000.00 KRW | +4.59% |
|
-20.19% | +37.13% |
| 10-14 | Pharmicell Secures KRW7.4 Billion Supply Deal With Doosan | MT |
| 10-08 | Doosan Business Research Institute announced that it expects to receive KRW 400 million in funding from Doosan Corporation | CI |
Company Valuation: Doosan Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,938,758 | 1,327,149 | 1,489,665 | 3,898,767 | 12,602,701 | 16,117,138 | - | - |
| Change | - | -31.55% | 12.25% | 161.72% | 223.25% | 27.89% | - | - |
| Enterprise Value (EV) 1 | 7,235 | 5,977 | 4,864 | 8,470 | 16,903 | 20,389 | 20,015 | 18,841 |
| Change | - | -17.4% | -18.62% | 74.13% | 99.57% | 20.63% | -1.84% | -5.87% |
| P/E | 9.92x | -2.12x | -4.3x | -20.1x | 186x | 25.5x | 23.3x | 18.1x |
| PBR | 0.74x | 0.63x | 0.98x | 2.66x | 8.53x | 7.96x | 6.55x | 4.86x |
| PEG | - | 0x | 0.1x | 0.5x | -1x | 0x | 2.44x | 0.6x |
| Capitalization / Revenue | 0.14x | 0.08x | 0.08x | 0.22x | 0.64x | 0.74x | 0.64x | 0.56x |
| EV / Revenue | 0.53x | 0.35x | 0.25x | 0.47x | 0.85x | 0.93x | 0.8x | 0.66x |
| EV / EBITDA | 4.6x | 3.41x | 2.27x | 4.78x | 9.03x | 7.76x | 6.18x | 4.75x |
| EV / EBIT | 7.55x | 5.31x | 3.39x | 8.45x | 15.9x | 11.4x | 8.06x | 5.75x |
| EV / FCF | 21.1x | -35.8x | 3.67x | -21x | 41x | 23.8x | 18.6x | 12.2x |
| FCF Yield | 4.74% | -2.79% | 27.2% | -4.75% | 2.44% | 4.2% | 5.37% | 8.2% |
| Dividend per Share 3 | 2,050 | 2,000 | 2,000 | 2,000 | 4,000 | 4,489 | 5,014 | 5,197 |
| Rate of return | 1.74% | 2.41% | 2.13% | 0.78% | 0.51% | 0.42% | 0.47% | 0.49% |
| EPS 3 | 11,890 | -39,123 | -21,823 | -12,715 | 4,194 | 41,996 | 46,012 | 59,036 |
| Distribution rate | 17.2% | -5.11% | -9.16% | -15.7% | 95.4% | 10.7% | 10.9% | 8.8% |
| Net sales 1 | 13,728 | 16,996 | 19,130 | 18,132 | 19,784 | 21,829 | 25,110 | 28,575 |
| EBITDA 1 | 1,571 | 1,751 | 2,141 | 1,771 | 1,871 | 2,629 | 3,239 | 3,969 |
| EBIT 1 | 958.8 | 1,126 | 1,435 | 1,003 | 1,063 | 1,794 | 2,482 | 3,279 |
| Net income 1 | 656.7 | -696.4 | -388.3 | -226.2 | 75.78 | 570.4 | 681.7 | 951.3 |
| Net Debt 1 | 5,297 | 4,649 | 3,374 | 4,571 | 4,300 | 4,272 | 3,898 | 2,724 |
| Reference price 3 | 118,000.00 | 83,100.00 | 93,900.00 | 255,000.00 | 781,000.00 | 1,071,000.00 | 1,071,000.00 | 1,071,000.00 |
| Nbr of stocks (in thousands) | 17,800 | 17,800 | 17,800 | 17,800 | 17,840 | 17,882 | - | - |
| Announcement Date | 11/02/22 | 07/03/23 | 31/01/24 | 24/01/25 | 10/02/26 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.38x | 0.9x | 7.48x | 0.44% | 11.54B | |
| 27.3x | 4.66x | 20.83x | 0.85% | 336B | |
| 35.44x | 5.51x | 30.01x | 1.02% | 173B | |
| 15.7x | 1.21x | 7.76x | 4.69% | 66.8B | |
| 18.62x | 1.73x | 14.04x | 2.93% | 58.33B | |
| 30.69x | 4.3x | 18.21x | 0.43% | 48.45B | |
| 16.11x | 1.63x | 9.35x | 2.69% | 40.66B | |
| 11.42x | 1.07x | 10.63x | 4.58% | 35.71B | |
| 32.05x | 4.67x | 18.6x | 1.56% | 30.7B | |
| 12.42x | 0.41x | 4.22x | 3.96% | 26.22B | |
| Average | 22.41x | 2.61x | 14.11x | 2.31% | 82.74B | |
| Weighted average by Cap. | 26.08x | 3.84x | 19.26x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- A000150 Stock
- Valuation Doosan Corporation
Select your edition
All financial news and data tailored to specific country editions
